Open access · US-GOV via ClinicalTrials.gov Clinical trial

Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors.

Authors not listed

University Hospital, Clermont-Ferrand · 2023

Epigenetic alterations Human Randomized controlled trial

Abstract

French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-21 MST

Cite this

APA

Anonymous. (2023). Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors. <em>University Hospital, Clermont-Ferrand</em>. https://clinicaltrials.gov/study/NCT06130787

Vancouver

Anonymous. Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors. University Hospital, Clermont-Ferrand. 2023.

BibTeX

@misc{anon2023Valueo, title = {Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors.}, author = {Anonymous}, journal = {University Hospital, Clermont-Ferrand}, year = {2023}, }